Reviewer’s report

Title: Phase I Study of TP300 in Patients with Advanced Solid Tumors with Pharmacokinetic, Pharmacogenetic and Pharmacodynamic Analyses

Version: 2 Date: 7 April 2012

Reviewer: Mark McKeage

Reviewer’s report:

Major Compulsory Revision
None

Minor Essential Revisions
Introduction Paragraph 2 sentence 1: Please refer to Fig 1 that shows the chemical structures of the prodrug, and its topoisomerase inhibitor and active metabolite.
Introduction Paragraph3 sentence 1 If this was the first-in-man trial of TP300 please say so here.

Results: Pharmacogenetic analysis: Sentence 1 Earlier in the paper mention was made about the role of AOX1 in TP300 metabolism, but no rationale for examining genetic variants of CYP26 and UGT1A1 is presented clearly here or elsewhere.
Results Pharmacodynamic analysis second sentence "TM" this abbreviation will not be familiar to many readers. Is it necessary or defined in the text?

Discussion paragraph 2 line 8: add dose units
Discussion last paragraph: Are there plans for further clinical evaluation of TP300

Discretionary Revisions
References
Reference 9 is incomplete

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:
'I declare that I have no competing interests’